Cargando…
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Milan
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112594/ https://www.ncbi.nlm.nih.gov/pubmed/35581545 http://dx.doi.org/10.1186/s10194-022-01423-x |
| _version_ | 1784709442655223808 |
|---|---|
| author | Nahas, Stephanie J. Naegel, Steffen Cohen, Joshua M. Ning, Xiaoping Janka, Lindsay Campos, Verena Ramirez Krasenbaum, Lynda J. Holle-Lee, Dagny Kudrow, David Lampl, Christian |
| author_facet | Nahas, Stephanie J. Naegel, Steffen Cohen, Joshua M. Ning, Xiaoping Janka, Lindsay Campos, Verena Ramirez Krasenbaum, Lynda J. Holle-Lee, Dagny Kudrow, David Lampl, Christian |
| author_sort | Nahas, Stephanie J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9112594 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Milan |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91125942022-05-18 Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies Nahas, Stephanie J. Naegel, Steffen Cohen, Joshua M. Ning, Xiaoping Janka, Lindsay Campos, Verena Ramirez Krasenbaum, Lynda J. Holle-Lee, Dagny Kudrow, David Lampl, Christian J Headache Pain Correction Springer Milan 2022-05-17 /pmc/articles/PMC9112594/ /pubmed/35581545 http://dx.doi.org/10.1186/s10194-022-01423-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Nahas, Stephanie J. Naegel, Steffen Cohen, Joshua M. Ning, Xiaoping Janka, Lindsay Campos, Verena Ramirez Krasenbaum, Lynda J. Holle-Lee, Dagny Kudrow, David Lampl, Christian Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_fullStr | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full_unstemmed | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_short | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_sort | correction: efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112594/ https://www.ncbi.nlm.nih.gov/pubmed/35581545 http://dx.doi.org/10.1186/s10194-022-01423-x |
| work_keys_str_mv | AT nahasstephaniej correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT naegelsteffen correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT cohenjoshuam correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT ningxiaoping correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT jankalindsay correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT camposverenaramirez correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT krasenbaumlyndaj correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT holleleedagny correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT kudrowdavid correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT lamplchristian correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies |